Clinical Trial

Trop2-targeted immunoPET Imaging of Solid Tumors

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-24; most recent amendment 2026-05-27.
Trial Details
NCT Number NCT06851663
Lead Sponsor RenJi Hospital
Conditions Solid Tumor, Solid Carcinoma, Uroepithelial Carcinoma, Bladder Cancer, Prostate Cancer, Lung Cancer, Nasopharyngeal Cancer, Liver Cancer +6 more
Enrollment 400 participants
Start Date 2024-12-23
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-29